Drug Profile
AC 701
Alternative Names: AC701Latest Information Update: 18 Oct 2021
Price :
$50
*
At a glance
- Originator TWi Biotechnology
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Exanthema; Rosacea
Most Recent Events
- 18 Oct 2021 AC 701 is still in phase II trial for Exanthema and Rosacea in Taiwan (Topical, Gel) (NCT04239846)
- 02 Oct 2019 TWi Biotechnology initiates enrolment in a phase II trial for Exanthema in Taiwan (Topical, Gel) (NCT04239846)
- 18 Feb 2019 AC 701 is still in phase II trials for Rosacea and Exanthema in Taiwan (Topical, Gel) (TWi Biotechnology pipeline, February 2019)